Aaron Winkler, PhD, Weiyong Sun, MS, Saurav De, PhD, Aiping Jiao, MD, M. Nusrat Sharif, PhD, Peter T. Symanowicz, MS, Shruti Athale, PhD, Julia H. Shin, MS, Ju Wang, MS, Bruce A. Jacobson, PhD, Simeon J. Ramsey, PhD, Ken Dower, PhD, Tatyana Andreyeva, MS, Heng Liu, MS, Martin Hegen1, PhD, Bruce L. Homer, DVM, PhD, Joanne Brodfuehrer, PhD, Mera Tilley, PhD, Steven A. Gilbert, PhD, Spencer I. Danto, MD, PhD, Jean J. Beebe1, PhD, Betsy J. Barnes, PhD, Virginia Pascual, MD, Lih-Ling Lin, PhD, Iain Kilty, PhD, Margaret Fleming, PhD, Vikram R. Rao, PhD. The IRAK4 kinase inhibitor PF-06650833 blocks inflammation in preclinical models of rheumatologic disease and in humans enrolled in a randomized clinical trial. Arthritis Rheumatol. (2021) https://doi.org/10.1002/art.41953.
Create a website or blog at WordPress.com